Rebecca A Snyder1, Jun He2, Jennifer Le-Rademacher2, Fang-Shu Ou3, Andrew B Dodge2, Tyler J Zemla2, Electra D Paskett4, George J Chang5, Federico Innocenti6, Charles Blanke7, Heinz-Josef Lenz8, Blasé N Polite9, Alan P Venook10. 1. Department of Surgery and Public Health, Brody School of Medicine at East Carolina University, Greenville, North Carolina. 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. College of Public Health, The Ohio State University, Columbus, Ohio. 5. Departments of Surgical Oncology and Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 7. Southwest Oncology Group Chair's Office and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 8. Department of Preventative Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California. 9. University of Chicago Comprehensive Cancer Center, Chicago, Illinois. 10. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Abstract
BACKGROUND: The objective of this study was to evaluate the association between self-identified race and overall survival (OS), progression-free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial. METHODS: Patients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model. RESULTS: In total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73-1.16), PFS (HR, 0.97; 95% CI, 0.78-1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65-1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02-1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18-1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22-2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24-0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72-1.65). CONCLUSIONS: No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial. LAY SUMMARY: Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer-specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression-free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.
BACKGROUND: The objective of this study was to evaluate the association between self-identified race and overall survival (OS), progression-free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial. METHODS: Patients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model. RESULTS: In total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73-1.16), PFS (HR, 0.97; 95% CI, 0.78-1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65-1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02-1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18-1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22-2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24-0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72-1.65). CONCLUSIONS: No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial. LAY SUMMARY: Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer-specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression-free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.
Authors: Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: M Peeters; G Kafatos; A Taylor; V M Gastanaga; K S Oliner; G Hechmati; J-H Terwey; J H van Krieken Journal: Eur J Cancer Date: 2015-06-03 Impact factor: 9.162
Authors: S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin Journal: Eur J Cancer Date: 2015-05-12 Impact factor: 9.162
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: Federico Innocenti; Fang-Shu Ou; Xueping Qu; Tyler J Zemla; Donna Niedzwiecki; Rachel Tam; Shilpi Mahajan; Richard M Goldberg; Monica M Bertagnolli; Charles D Blanke; Hanna Sanoff; James Atkins; Blasé Polite; Alan P Venook; Heinz-Josef Lenz; Omar Kabbarah Journal: J Clin Oncol Date: 2019-03-13 Impact factor: 44.544
Authors: Hanna K Sanoff; Daniel J Sargent; Erin M Green; Howard L McLeod; Richard M Goldberg Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544
Authors: Heinz-Josef Lenz; Fang-Shu Ou; Alan P Venook; Howard S Hochster; Donna Niedzwiecki; Richard M Goldberg; Robert J Mayer; Monica M Bertagnolli; Charles D Blanke; Tyler Zemla; Xueping Qu; Pratyaksha Wirapati; Sabine Tejpar; Federico Innocenti; Omar Kabbarah Journal: J Clin Oncol Date: 2019-05-01 Impact factor: 50.717
Authors: Robert P Jones; Paul A Sutton; Jonathan P Evans; Rachel Clifford; Andrew McAvoy; James Lewis; Abigail Rousseau; Roger Mountford; Derek McWhirter; Hassan Z Malik Journal: Br J Cancer Date: 2017-02-16 Impact factor: 7.640